White papers, webinars, case studies, regulatory guides, and insights on AI-driven benefit-risk analysis for pharmaceutical development.
A comprehensive analysis of how AI-driven benefit-risk assessment is transforming pharmaceutical development timelines and regulatory submission quality across oncology, cardiovascular, and rare disease programs.
Showing 24 resources
Quantitative frameworks for structured benefit-risk assessment in oncology drug development programs. Covers BRAT, MCDA, value trees, and regulatory alignment.
Dr. Sarah Chen
On-demand webinar covering real-world evidence integration in cardiovascular benefit-risk assessment, including EHR data and claims databases.
Dr. James Morgan
Watch Now →How a top-10 pharma company reduced BRA timelines by 60% using ArcaScience for their oncology submission.
ArcaScience Team
Read Case Study →Newsletter
Receive the latest white papers, regulatory updates, and benefit-risk analysis insights delivered to your inbox. No more than twice per month.
By subscribing you agree to our Privacy Policy. Unsubscribe at any time.
